Abstract:Increasing evidence suggests that free haem and iron exert vasculo-toxic and pro-inflammatory effects by activating endothelial and immune cells. In the present retrospective study, we compared serum samples from transfusion-dependent patients with β-thalassaemia major and intermedia, hereditary spherocytosis and sickle cell disease (SCD). Haemolysis, transfusions and ineffective erythropoiesis contribute to haem and iron overload in haemolytic patients. In all cohorts we observed increased systemic haem and iron levels associated with scavenger depletion and toxic 'free' species formation. Endothelial dysfunction, oxidative stress and inflammation markers were significantly increased compared to healthy donors. In multivariable logistic regression analysis, oxidative stress markers remained significantly associated with both haem- and iron-related parameters, while soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble endothelial selectin (sE-selectin) and tumour necrosis factor α (TNFα) showed the strongest association with haem-related parameters and soluble intercellular adhesion molecule 1 (sICAM-1), sVCAM-1, interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) with iron-related parameters. While hereditary spherocytosis was associated with the highest IL-6 and TNFα levels, β-thalassaemia major showed limited inflammation compared to SCD. The sVCAM1 increase was significantly lower in patients with SCD receiving exchange compared to simple transfusions. The present results support the involvement of free haem/iron species in the pathogenesis of vascular dysfunction and sterile inflammation in haemolytic diseases, irrespective of the underlying haemolytic mechanism, and highlight the potential therapeutic benefit of iron/haem scavenging therapies in these conditions.

Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat

Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Cardiac complications in thalassemia throughout the lifespan: Victories and challenges

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease

Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron?

The role of extracellular vesicles on the occurrence of clinical complications in β-thalassemia

Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in transfusion-dependent patients with haemolytic anaemias

Αlpha-thalassemia: A practical overview

Changing patterns in the epidemiology of β‐thalassemia

Iron overload: the Achilles heel of β- thalassemia

Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition

How I manage medical complications of β-thalassemia in adults

Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness

Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

Hemosiderosis causing liver cirrhosis in a patient with Hb S/beta thalassemia and no other known causes of hepatic disease

Thalassemia: An Overview of 50 Years of Clinical Research

Natural Anticoagulant Protein Levels in Patients With Beta-Thalassemia Major: A Case-Control Study

Anemia and iron overload as prognostic markers of outcomes in β-thalassemia

Endocrinopathies in beta thalassemia: a narrative review

[Hemostasis alterations in sickle cell syndrome]